

STN Search History

Connecting via Winsock to STN

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s trospium/cn

L1 1 TROSPiUM/CN

=> d 11

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN

RN 47608-32-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, (1 α ,3 α ,5 α)- (CA
INDEX NAME)

OTHER CA INDEX NAMES:

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
3-[(hydroxydiphenylacetyl)oxy]-, (1 α ,3 α ,5 α)- (9CI)

OTHER NAMES:

CN Trospium

CN Trospium cation

FS STEREOSEARCH


DR 50857-35-7, 112726-87-1

MF C25 H30 N O3

CI COM

LC STN Files: ADISNEWS, BEILSTEIN*, BIOSIS, CA, CAPLUS, CIN, DDFU, DRUGU,
IMSRESEARCH, IPA, PROMT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Relative stereochemistry:



50 REFERENCES IN FILE CA (1907 TO DATE)

13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

50 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s trospium

L2 3 TROSPiUM

=> d 12 1-3

L2 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 47608-32-2 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
 3-[(2-hydroxy-2-diphenylacetyl)oxy]-, (1 α ,3 α ,5 α)- (CA
 INDEX NAME)

OTHER CA INDEX NAMES:

CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
 3-[(hydroxydiphenylacetyl)oxy]-, (1 α ,3 α ,5 α)- (9CI)

OTHER NAMES:

CN Trospium

CN Trospium cation

FS STEREOSEARCH


DR 50857-35-7, 112726-87-1

MF C25 H30 N O3

CI COM

LC STN Files: ADISNEWS, BEILSTEIN*, BIOSIS, CA, CAPLUS, CIN, DDFU, DRUGU,
 IMSRESEARCH, IPA, PROMT, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)

Relative stereochemistry.



50 REFERENCES IN FILE CA (1907 TO DATE)
 13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 50 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 30806-20-3 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
 3-[(hydroxydiphenylacetyl)oxy]-, (1 α ,3 β ,5 α)-, salt with
 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1) (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, ion(1-),
 (1 α ,3 β ,5 α)-3-[(hydroxydiphenylacetyl)oxy]spiro[8-
 aponiabicyclo[3.2.1]octane-8,1'-pyrrolidinium] (9CI)
 CN Spiro[1 α H,5 α H-nortropane-8,1'-pyrrolidinium],
 3 α -hydroxy-, salt with 1,2-benzisothiazolin-3-one 1,1-dioxide (1:1),
 benzilate (ester) (8CI)
 OTHER NAMES:
 CN Trospium salt with 1,2-benzisothiazol-3(2H)-one 1,1-dioxide (1:1)
 FS STEREOSEARCH


3

MF C25 H30 N O3 . C7 H4 N O3 S
LC STN Files: CA, CAPLUS

CM 1


CRN 47608-32-2
CMF C25 H30 N O3

Relative stereochemistry.



CM 2

CRN 16766-82-8
CMF C7 H4 N O3 S



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2007 ACS on STN
RN 10405-02-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, chloride (1:1),
(1 α ,3 β ,5 α)- (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN Benzilic acid, ester with 3 α -hydroxyspiro[1 α H,5 α H-nortropane-8,1'-pyrrolidinium] chloride (8CI)
CN Spiro[1 α H,5 α H-nortropane-8,1'-pyrrolidinium],
3 α -hydroxy-, chloride, benzilate (8CI)
CN Spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium],
3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1 α ,3 β ,5 α)- (9CI)

OTHER NAMES:

CN As XVII
CN Azoniaspiro compound XVII

CN Azoniaspiro(3 α -benziloyloxyxanthropine-8,1'-pyrrolidine) chloride
 CN Keptan
 CN Relaspium
 CN Sanctura
 CN Spasmex
 CN Spasmo 3
 CN Spasmo-lyt
 CN Trospium chloride
 FS STEREOSEARCH
 MF C25 H30 N O3 . Cl
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,
 DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PS, RTECS*, SCISEARCH,
 TOXCENTER, USAN, USPAT2, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (47608-32-2)

Relative stereochemistry.



● Cl⁻

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

110 REFERENCES IN FILE CA (1907 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 110 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus uspatfull medline biosis ps			
COST IN U.S. DOLLARS	SINCE FILE		TOTAL
FULL ESTIMATED COST	ENTRY		SESSION
	19.95		20.16

FILE 'CAPLUS' ENTERED AT 15:43:43 ON 02 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:43:43 ON 02 OCT 2007
 CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:43:43 ON 02 OCT 2007

FILE 'BIOSIS' ENTERED AT 15:43:43 ON 02 OCT 2007
 Copyright (c) 2007 The Thomson Corporation

FILE 'PS' ENTERED AT 15:43:43 ON 02 OCT 2007
 COPYRIGHT (C) 2007 Thieme on STN

=> s 11 or trospium
 L3 686 L1 OR TROPIUM

=> fil registry
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 6.15 26.31

FILE 'REGISTRY' ENTERED AT 15:44:35 ON 02 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7
 DICTIONARY FILE UPDATES: 1 OCT 2007 HIGHEST RN 948988-82-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s formoterol/cn
 L4 1 FORMOTEROL/CN

=> d 14

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 73573-87-2 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, rel- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[(2-(4-methoxyphenyl)-1-methylethyl)amino]ethyl]phenyl]-, (R*,R*)-(±)-
 OTHER NAMES:
 CN (±)Formoterol
 CN Eformoterol
 CN Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[(2-(4-methoxyphenyl)-1-methylethyl)amino]ethyl]phenyl]-, (R*,R*)-(±)-
 CN Formoterol
 CN Oxis
 FS STEREOSEARCH

DR 126587-85-7, 49861-99-6, 183814-29-1

MF C19 H24 N2 O4


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, HSDB*, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

779 REFERENCES IN FILE CA (1907 TO DATE)

26 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

784 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s leucine/cn

L5 2 LEUCINE/CN

=> d 15 1-2

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN

RN 328-39-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN Leucine (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN DL-Leucine

CN Leucine, DL- (8CI)

OTHER NAMES:

CN (+)-Leucine

CN (RS)-Leucine

CN NSC 9252

MF C6 H13 N O2


CI COM

LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DETHERM*, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, PIRA, PROMT, SPECINFO, TOXCENTER, TULSA, USPAT2, USPATFULL, USPATOLD

(*File contains numerically searchable property data)

Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1365 REFERENCES IN FILE CA (1907 TO DATE)
 42 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1371 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 61-90-5 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN L-Leucine (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Leucine, L- (8CI)
 OTHER NAMES:
 CN (2S)-2-Amino-4-methylpentanoic acid
 CN (S)-(+)-Leucine
 CN (S)-2-Amino-4-methylpentanoic acid
 CN (S)-2-Amino-4-methylvaleric acid
 CN (S)-Leucine
 CN 100: PN: US20070066537 PAGE: 17 claimed sequence
 CN L-(+)-Leucine
 CN L- α -Aminoisopropanoic acid
 CN L-Norvaline, 4-methyl-
 CN Leu
 CN Leucine
 CN NSC 46709
 CN Pentanoic acid, 2-amino-4-methyl-, (S)-
 FS STEREOSEARCH
 DR 7005-03-0
 MF C6 H13 N O2
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU,
 EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS,
 NAPRALERT, PATDPASPC, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE,
 TOXCENTER, TULSA, USAN, USPAT2, USPATFULL, USPATOLD
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

38014 REFERENCES IN FILE CA (1907 TO DATE)

815 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 38094 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> fil caplus uspatfull medline biosis ps

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	16.65	42.96

FILE 'CAPLUS' ENTERED AT 15:45:50 ON 02 OCT 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:45:50 ON 02 OCT 2007

CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 15:45:50 ON 02 OCT 2007

FILE 'BIOSIS' ENTERED AT 15:45:50 ON 02 OCT 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'PS' ENTERED AT 15:45:50 ON 02 OCT 2007

COPYRIGHT (C) 2007 Thieme on STN

=> d hist

(FILE 'HOME' ENTERED AT 15:40:42 ON 02 OCT 2007)

FILE 'REGISTRY' ENTERED AT 15:40:58 ON 02 OCT 2007

L1	1 S TROSPIUM/CN
L2	3 S TROSPIUM

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:43:43 ON 02 OCT 2007

L3	686 S L1 OR TROSPIUM
----	----------------------

FILE 'REGISTRY' ENTERED AT 15:44:35 ON 02 OCT 2007

L4	1 S FORMOTEROL/CN
L5	2 S LEUCINE/CN

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:45:50 ON 02 OCT 2007

=> s l3 and (l4 or formoterol) and (l5 or leucine)

L6	20 L3 AND (L4 OR FORMOTEROL) AND (L5 OR LEUCINE)
----	--

=> d 16 ibib abs 1-20

L6 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:202111 CAPLUS Full-text

DOCUMENT NUMBER: 146:259006

TITLE: Trospium-containing compositions

INVENTOR(S): Ehrich, Elliot; Deaver, Daniel; Clarke, Robert; Lipp, Michael M.

PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 392,333.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007041912	A1	20070222	US 2006-550471	20060901
US 2004042970	A1	20040304	US 2003-392333	20030319
CA 2517265	A1	20041104	CA 2003-2517265	20030904
WO 2004093861	A1	20041104	WO 2003-US27618	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273273	A1	20041119	AU 2003-273273	20030904
AU 2003273273	B2	20070208		
EP 1603547	A1	20051214	EP 2003-755776	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514679	T	20060511	JP 2004-571157	20030904
IN 2005DN03513	A	20070817	IN 2005-DN3513	20050808
MX 2005PA09629	A	20051018	MX 2005-PA9629	20050908
AU 2006220411	A1	20061012	AU 2006-220411	20060920
PRIORITY APPLN. INFO.:			US 2003-392333	A2 20030319
			WO 2003-US27618	W 20030904
			US 2002-366354P	P 20020320
			US 2002-366440P	P 20020320
			US 2002-366449P	P 20020320
			US 2002-366470P	P 20020320
			US 2002-366479P	P 20020320
			US 2002-366487P	P 20020320
			AU 2003-230689	A3 20030319

AB The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 h. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

L6 ANSWER 2 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2007:250600 USPATFULL Full-text
 TITLE: Chromane Derivatives
 INVENTOR(S): Matsumoto, Yukari, Chita-gun, JAPAN
 Shimokawa, Hirohisa, Chita-gun, JAPAN
 Yamagishi, Tatsuya, Chita-gun, JAPAN
 PATENT ASSIGNEE(S): Pfizer Inc (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2007219237 A1 20070920
 APPLICATION INFO.: US 2007-687781 A1 20070319 (11)

NUMBER DATE

PRIORITY INFORMATION: US 2006-804872P 20060615 (60)
 US 2006-783663P 20060317 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US

NUMBER OF CLAIMS: 11

EXEMPLARY CLAIM: 1-10

LINE COUNT: 2750

AB This invention relates to compounds of the formula (I):

##STR1##

or a pharmaceutically acceptable salt thereof, wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 A and B are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastrolesophageal disease, gastrolesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

L6 ANSWER 3 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2007:170907 USPATFULL Full-text
 TITLE: Compounds having lysophosphatidic acid receptor antagonism and uses thereof
 INVENTOR(S): Tanaka, Motoyuki, Mishima-gun, JAPAN
 Nakade, Shinji, Tsukuba-shi, JAPAN
 Takaoka, Yoshikazu, Mishima-gun, JAPAN

NUMBER KIND DATE

PATENT INFORMATION: US 2007149595 A1 20070628
 APPLICATION INFO.: US 2004-583469 A1 20041217 (10)
 WO 2004-JP19456 20041217
 20060619 PCT 371 date

NUMBER DATE

PRIORITY INFORMATION: JP 2003-422431 20031219
 JP 2004-101378 20040330

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM:

1

LINE COUNT:

5101

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound represented by formula (I): ##STR1## (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic hypertrophy or neurogenic bladder dysfunction disease, spinal cord neoplasm, nucleous hernia, spinal canal stenosis, diseases caused by diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, and polyuria), carcinoma-associated disease, proliferative disease, inflammation system disease, immune system disease, disease by secretory dysfunction, brain-related disease and/or chronic disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2007:162891 USPATFULL Full-text

TITLE: Chromane Substituted Benzimidazole Derivatives

INVENTOR(S): Hanazawa, Takeshi, Chita-gun, JAPAN

Koike, Hiroki, Chita-gun, JAPAN

PATENT ASSIGNEE(S): Pfizer Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007142448	A1	20070621
APPLICATION INFO.:	US 2006-612583	A1	20061219 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-752181P	20051219 (60)
	US 2006-802944P	20060523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3694	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2007:151356 USPATFULL Full-text
 TITLE: MULTI-SAMPLE MICROFLUIDIC DIELECTROPHORESIS SEPARATING
 DEVICE AND METHOD THEREOF
 INVENTOR(S): Yu, Tung-Ming, Hsinchu, TAIWAN, PROVINCE OF CHINA
 Liu, Cheng-Hsiang, Hsinchu, TAIWAN, PROVINCE OF CHINA
 PATENT ASSIGNEE(S): Industrial Technology Research Institute, Hsinchu,
 TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007131554	A1	20070614
APPLICATION INFO.:	US 2006-550471	A1	20061018 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	TW 2005-94143722	20051209
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MICHAEL W. TAYLOR, 255 South Orange Avenue, Suite 1401, P.O. Box 3791, Orlando, FL, 32801-3460, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	303	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A microfluidic dielectrophoresis separating device is provided. The microfluidic dielectrophoresis separating device includes a primary passage, at least a secondary passage and at least an electrode assembly. The primary passage has a primary flow containing a plurality of particulates flowing therein. The secondary passage has an input path and an output path and is connected with the primary passage. The electrode assembly generates a dielectrophoresis force to drive a specific one of the particulates into the output path.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2007:75023 USPATFULL Full-text
 TITLE: Mucoactive agents for treating a pulmonary disease
 INVENTOR(S): Morton, David, Wiltshire, UNITED KINGDOM
 Ganderton, David, Wiltshire, UNITED KINGDOM
 Staniforth, John, Wiltshire, UNITED KINGDOM
 Kamlag, Yorick, Wiltshire, UNITED KINGDOM
 PATENT ASSIGNEE(S): Vectura Ltd., Chippenham, Wiltshire, GBN, UNITED KINGDOM, SN14 6FH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007065373	A1	20070322
APPLICATION INFO.:	US 2004-571184	A1	20040915 (10)
	WO 2004-GB3932		20040915
			20060717 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-21611	20030915
	GB 2003-27723	20031128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE,
14TH FLOOR, NEW YORK, NY, 10018, US

NUMBER OF CLAIMS: 46

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 1903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It also relates to methods for producing particles suitable for pulmonary inhalation, such as spray drying or jet milling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2007:48090 USPATFULL Full-text

TITLE: Trospium containing compositions

INVENTOR(S): Ehrich, Elliot, Lincoln, MA, UNITED STATES

Deaver, Daniel, Franklin, MA, UNITED STATES

Clarke, Robert, Canton, MA, UNITED STATES

Lipp, Michael M., Framingham, MA, UNITED STATES

PATENT ASSIGNEE(S): ADVANCED INHALATION RESEARCH, INC., Cambridge, MA,
UNITED STATES, 02139 (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

-----	-----	-----
-------	-------	-------

PATENT INFORMATION: US 2007041912 A1 20070222

APPLICATION INFO.: US 2003-550471 A1 20030904 (10)

WO 2003-US27618 20030904

20060901 PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-392333, filed
on 19 Mar 2003, PENDING

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ELMORE PATENT LAW GROUP, PC, 209 MAIN STREET, N.
CHELMSFORD, MA, 01863, US

NUMBER OF CLAIMS: 28

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 587

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 hours. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol composition is manufactured by spray drying a mixture comprising trospium and formoterol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2007:12284 USPATFULL Full-text
 TITLE: Safety containers for biologically active substances
 and method for producing said container
 INVENTOR(S): Bensmann, Hubert, Halle/Westfalen, GERMANY, FEDERAL
 REPUBLIC OF
 Kranzmann, Heiko, Bielefeld, GERMANY, FEDERAL REPUBLIC
 OF
 Milsmann, Eckhard, Bielefeld, GERMANY, FEDERAL REPUBLIC
 OF
 Wichert, Burkhard, Bielefeld, GERMANY, FEDERAL REPUBLIC
 OF
 PATENT ASSIGNEE(S): Baxter International Inc, Deerfield, IL, UNITED STATES,
 60015 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007010700	A1	20070111
APPLICATION INFO.:	US 2004-541692	A1	20040109 (10)
	WO 2004-EP98		20040109
			20060829 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-60438822	20030109
	DE 2001-103003231	20010109
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SENNIGER POWERS, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102, US	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1-56	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2108	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to safety containers for biologically active substances, in particular cytostatic agents, said container having increased or higher fracture strength and shatterproof qualities, in addition to an uncontaminated exterior. The invention also relates to a method for producing said containers and to the use of a medium containing at least one polymer for decontaminating the exterior of a container that is filled with a biologically active substance, sealed and optionally labelled.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 9 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2006:301136 USPATFULL Full-text
 TITLE: Dry powder composition comprising co-jet milled
 particles for pulmonary inhalation
 INVENTOR(S): Morton, David, Wiltshire, UNITED KINGDOM
 Staniforth, John, Wiltshire, UNITED KINGDOM
 PATENT ASSIGNEE(S): Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006257491	A1	20061116
APPLICATION INFO.:	US 2004-571146	A1	20040915 (10)
	WO 2004-GB3996		20040915
			20060717 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-21612	20030915
	GB 2003-21608	20030915
	GB 2003-21607	20030915
	GB 2004-9133	20040423
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018, US	
NUMBER OF CLAIMS:	41	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1996	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 10 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2006:227550 USPATFULL Full-text
 TITLE: Crush resistant delayed-release dosage forms
 INVENTOR(S): Ashworth, Judy, Wermelskirchen, GERMANY, FEDERAL
 REPUBLIC OF
 Arkenau Maric, Elisabeth, Koln, GERMANY, FEDERAL
 REPUBLIC OF
 Bartholomaeus, Johannes, Aachen, GERMANY, FEDERAL
 REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006193914	A1	20060831
APPLICATION INFO.:	US 2006-348295	A1	20060206 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-10200500544620050204	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PERMAN & GREEN, 425 POST ROAD, FAIRFIELD, CT, 06824, US	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2689	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substances (A) from the dosage form is at least partially delayed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 11 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2006:130791 USPATFULL Full-text
 TITLE: Methods and devices for the treatment of ocular
 conditions
 INVENTOR(S): deJuan, Eugene, LaCanada, CA, UNITED STATES
 Varner, Signe E., Los Angeles, CA, UNITED STATES
 Lawin, Laurie R., New Brighton, MN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006110428	A1	20060525
APPLICATION INFO.:	US 2005-175850	A1	20050705 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-585236P	20040702 (60)
	US 2005-669701P	20050408 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCOTT PRIBNOW, Kagan Binder, PLLC, Suite 200, 221 Main Street North, Stillwater, MN, 55082, US	
NUMBER OF CLAIMS:	48	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	4502	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A) - (C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 12 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2005:27398 USPATFULL Full-text
 TITLE: Low dose pharmaceutical powders for inhalation
 INVENTOR(S): Hrkach, Jeffrey S., Lexington, MA, UNITED STATES
 PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., Cambridge, MA,
 UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005022812	A1	20050203
APPLICATION INFO.:	US 2004-867375	A1	20040614 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-478315P	20030613 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELMORE CRAIG, P.C., 209 MAIN STREET, N. CHELMSFORD, MA,	

01863

NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 20 Drawing Page(s)
 LINE COUNT: 1165

AB The invention relates to a method of delivering an agent to the pulmonary system of a compromised patient, in a single breath-activated step, comprising administering a particle mass comprising an agent from an inhaler containing less than 5 milligrams of the mass, wherein at least about 50% of the mass in the receptacle is delivered to the pulmonary system of a patient. The invention also relates to receptacles containing the particle mass and the inhaler for use therein.

L6 ANSWER 13 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2005:17275 USPATFULL Full-text
 TITLE: Solid peptide preparations for inhalation and their preparation
 INVENTOR(S): Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC OF
 Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF
 Sarlikiotis, Werner, Peania, GREECE
 Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005014677	A1	20050120
APPLICATION INFO.:	US 2004-808239	A1	20040323 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-944060, filed on 31 Aug 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10043509	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GOODWIN PROCTER L.L.P, 103 EISENHOWER PARKWAY, ROSELAND, NJ, 07068	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	731	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 14 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2005:3763 USPATFULL Full-text
 TITLE: Diagnostic/therapeutic agents
 INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
 Rongved, Pal, Oslo, NORWAY
 Hogset, Anders, Oslo, NORWAY
 Tolleshaug, Helge, Oslo, NORWAY

Cuthbertson, Alan, Oslo, NORWAY
 Godal, Aslak, Oslo, NORWAY
 Hoff, Lars, Oslo, NORWAY
 Gogstad, Geir, Oslo, NORWAY
 Bryn, Klaus, Oslo, NORWAY
 Naevestad, Anne, Oslo, NORWAY
 Lovhaug, Dagfinn, Oslo, NORWAY
 Hellebust, Halldis, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S) : Amersham Health AS, Oslo, NORWAY (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2005002865 A1 20050106
 APPLICATION INFO.: US 2003-734730 A1 20031215 (10)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-925715, filed on 10 Aug 2001, GRANTED, Pat. No. US 6680047 Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, GRANTED, Pat. No. US 6331289

NUMBER	DATE
--------	------

PRIORITY INFORMATION: GB 1996-22366 19961028
 GB 1996-22369 19961028
 GB 1997-2195 19970204
 GB 1997-8265 19970424
 GB 1997-11837 19970606
 GB 1997-11839 19970606
 US 1997-49263P 19970607 (60)
 US 1997-49264P 19970606 (60)
 US 1997-49266P 19970607 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Li CAI, Amersham Health, Inc., 101 Carnegie Center, Princeton, NJ, 08540-6231

NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1

LINE COUNT: 5221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 15 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2004:184041 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
 Rongved, Pal, Oslo, NORWAY
 Hogset, Anders, Oslo, NORWAY
 Tolleshaug, Helge, Oslo, NORWAY
 Naevestad, Anne, Oslo, NORWAY
 Hellebust, Halldis, Oslo, NORWAY
 Hoff, Lars, Oslo, NORWAY
 Cuthbertson, Alan, Oslo, NORWAY
 Lovhaug, Dagfinn, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S) : NYCOMED IMAGING AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004141922	A1	20040722
APPLICATION INFO.:	US 2003-722075	A1	20031126 (10)
RELATED APPLN. INFO. :	Continuation of Ser. No. US 2001-765614, filed on 22 Jan 2001, ABANDONED Continuation of Ser. No. US 1997-960054, filed on 29 Oct 1997, GRANTED, Pat. No. US 6261537 Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997, GRANTED, Pat. No. US 6264917		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970606 (60)
	US 1997-49265P	19970606 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Li CAI, Amersham Health, Inc., 101 Carnegie Center, Princeton, NJ, 08540-6231

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 6450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 16 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2004:56968 USPATFULL Full-text

TITLE: Inhalable sustained therapeutic formulations

INVENTOR(S): Basu, Sujit K., Cambridge, MA, UNITED STATES

Caponetti, Giovanni, Piacenza, ITALY

Clarke, Robert, Canton, MA, UNITED STATES

Elbert, Katharina J., Cambridge, MA, UNITED STATES

PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004042970	A1	20040304
APPLICATION INFO.:	US 2003-392333	A1	20030319 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-366479P	20020320 (60)

US 2002-366449P	20020320 (60)
US 2002-366354P	20020320 (60)
US 2002-366470P	20020320 (60)
US 2002-366487P	20020320 (60)
US 2002-366440P	20020320 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Elmore Craig, P.C., 209 Main Street, No. Chelmsford, MA, 01863
 NUMBER OF CLAIMS: 58
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Page(s)
 LINE COUNT: 2838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 20 USPATFULL on STN
 ACCESSION NUMBER: 2003:329808 USPATFULL Full-text
 TITLE: Inhalable formulations for sustained release
 INVENTOR(S): Basu, Sujit K., Cambridge, MA, UNITED STATES
 Elbert, Katharina, Cambridge, MA, UNITED STATES
 Hrkach, Jeffrey, Cambridge, MA, UNITED STATES
 Caponetti, Giovanni, Piacenza, ITALY
 PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., Cambridge, MA (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----
PATENT INFORMATION: US 2003232019	A1	20031218
APPLICATION INFO.: US 2003-371398	A1	20030220 (10)

NUMBER	DATE
-----	-----
PRIORITY INFORMATION: US 2002-427845P	20021120 (60)
US 2002-359466P	20020222 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Elmore Craig, P.C., 209 Main Street, No. Chelmsford, MA, 01863
 NUMBER OF CLAIMS: 123
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 4 Drawing Page(s)
 LINE COUNT: 2281

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based, in part, on the unexpected discovery that aerosol particle formulations for pulmonary delivery of a therapeutic,

prophylactic or diagnostic agent comprising an asymmetric phospholipid exhibit sustained release and/or sustained action of the agent. In some embodiments, as an alternative to one or more asymmetric phospholipids or in addition to one or more asymmetric phospholipids, the instant particles comprise one or more glycerol fatty acid esters. The present invention is directed to spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent and methods for delivery of said particles to the pulmonary system, the particles comprising a therapeutic, prophylactic or diagnostic agent and an asymmetric phospholipid and/or one or more glycerol fatty acid esters. In one embodiment, the particles comprise a combination of phospholipids wherein at least one of the phospholipids is an asymmetric phospholipid. In another embodiment, the particles comprise one or more phospholipids and one or more glycerol fatty acid esters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:227675 USPATFULL Full-text

TITLE: Solid peptide preparations for inhalation and their preparation

INVENTOR(S): Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC OF
Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF
Sarlikiotis, Werner, Peania, GREECE
Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL
REPUBLIC OF

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002122826 A1 20020905

APPLICATION INFO.: US 2001-944060 A1 20010831 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: DE 2000-10043509 20000901

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Goodwin Procter L.L.P., 599 Lexington Avenue, 40th floor, New York, NY, 10022

NUMBER OF CLAIMS: 23

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:191154 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S): Klaveness, Jo, Oslo, NORWAY

Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY

Tolleshaug, Helge, Oslo, NORWAY

Cuthbertson, Alan, Oslo, NORWAY
 Godal, Aslak, Oslo, NORWAY
 Hoff, Lars, Oslo, NORWAY
 Gogstad, Geir, Oslo, NORWAY
 Bryn, Klaus, Oslo, NORWAY
 Naevestad, Anne, Oslo, NORWAY
 Lovhaug, Dagfinn, Oslo, NORWAY
 Hellebust, Halldis, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S) : Nycomed Imaging AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102217	A1	20020801
APPLICATION INFO.:	US 6680047	B2	20040120
RELATED APPLN. INFO.:	US 2001-925715	A1	20010810 (9) Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970607 (60)
	US 1997-49264P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Richard E. Fichter, BACON & THOMAS, PLLC, Fourth Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176

NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 1 Drawing Page(s)

LINE COUNT: 5190

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 20 OF 20 USPATFULL on STN

ACCESSION NUMBER: 2002:191152 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S): Klaveness, Jo, Oslo, NORWAY

Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY

Tolleshaug, Helge, Oslo, NORWAY

Naevestad, Anne, Oslo, NORWAY

Hellebust, Halldis, Oslo, NORWAY

Hoff, Lars, Oslo, NORWAY

Cuthbertson, Alan, Oslo, NORWAY

Lovhaug, Dagfinn, Oslo, NORWAY

Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S): NYCOMED IMAGING AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102215	A1	20020801
APPLICATION INFO.:	US 2001-765614	A1	20010122 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-960054, filed on 29 Oct 1997, PATENTED Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970606 (60)
	US 1997-49265P	19970606 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BACON & THOMAS, PLLC, 4th Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 6583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilized by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> s phospholipid
 L7 341233 PHOSPHOLIPID

=> s 16 and 17
 L8 16 L6 AND L7

=> duplicate
 ENTER REMOVE, IDENTIFY, ONLY, OR (?) :remove
 ENTER L# LIST OR (END) :18
 DUPLICATE IS NOT AVAILABLE IN 'PS'.
 ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
 DUPLICATE PREFERENCE IS 'CAPLUS, USPATFULL'
 KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N) :n
 PROCESSING COMPLETED FOR L8
 L9 15 DUPLICATE REMOVE L8 (1 DUPLICATE REMOVED)

=> d hist

(FILE 'HOME' ENTERED AT 15:40:42 ON 02 OCT 2007)

FILE 'REGISTRY' ENTERED AT 15:40:58 ON 02 OCT 2007
L1 1 S TROSPIUM/CN
L2 3 S TROSPIUM

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:43:43 ON 02 OCT 2007
L3 686 S L1 OR TROSPIUM

FILE 'REGISTRY' ENTERED AT 15:44:35 ON 02 OCT 2007
L4 1 S FORMOTEROL/CN
L5 2 S LEUCINE/CN

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:45:50 ON 02 OCT 2007
L6 20 S L3 AND (L4 OR FORMOTEROL) AND (L5 OR LEUCINE)
L7 341233 S PHOSPHOLIPID
L8 16 S L6 AND L7
L9 15 DUPLICATE REMOVE L8 (1 DUPLICATE REMOVED)

=> s l3 and inhal?
L10 163 L3 AND INHAL?

=> s l10 and (l5 or leucine)
L11 20 L10 AND (L5 OR LEUCINE)

=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l10
DUPLICATE IS NOT AVAILABLE IN 'PS'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
DUPLICATE PREFERENCE IS 'CAPLUS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n
PROCESSING COMPLETED FOR L10
L12 159 DUPLICATE REMOVE L10 (4 DUPLICATES REMOVED)

=> d hist

(FILE 'HOME' ENTERED AT 15:40:42 ON 02 OCT 2007)

FILE 'REGISTRY' ENTERED AT 15:40:58 ON 02 OCT 2007
L1 1 S TROSPIUM/CN
L2 3 S TROSPIUM

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:43:43 ON 02 OCT 2007
L3 686 S L1 OR TROSPIUM

FILE 'REGISTRY' ENTERED AT 15:44:35 ON 02 OCT 2007
L4 1 S FORMOTEROL/CN
L5 2 S LEUCINE/CN

FILE 'CAPLUS, USPATFULL, MEDLINE, BIOSIS, PS' ENTERED AT 15:45:50 ON 02 OCT 2007
L6 20 S L3 AND (L4 OR FORMOTEROL) AND (L5 OR LEUCINE)
L7 341233 S PHOSPHOLIPID
L8 16 S L6 AND L7
L9 15 DUPLICATE REMOVE L8 (1 DUPLICATE REMOVED)
L10 163 S L3 AND INHAL?
L11 20 S L10 AND (L5 OR LEUCINE)
L12 159 DUPLICATE REMOVE L10 (4 DUPLICATES REMOVED)

=> d 19 ibib abs 1-16

L9 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2007:202111 CAPLUS Full-text
 DOCUMENT NUMBER: 146:259006
 TITLE: Trospium-containing compositions
 INVENTOR(S): Ehrich, Elliot; Deaver, Daniel; Clarke, Robert; Lipp, Michael M.
 PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S.
 Ser. No. 392,333.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007041912	A1	20070222	US 2006-550471	20060901
US 2004042970	A1	20040304	US 2003-392333	20030319
CA 2517265	A1	20041104	CA 2003-2517265	20030904
WO 2004093861	A1	20041104	WO 2003-US27618	20030904
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003273273	A1	20041119	AU 2003-273273	20030904
AU 2003273273	B2	20070208		
EP 1603547	A1	20051214	EP 2003-755776	20030904
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514679	T	20060511	JP 2004-571157	20030904
IN 2005DN03513	A	20070817	IN 2005-DN3513	20050808
MX 2005PA09629	A	20051018	MX 2005-PA9629	20050908
AU 2006220411	A1	20061012	AU 2006-220411	20060920
PRIORITY APPLN. INFO.:				
			US 2003-392333	A2 20030319
			WO 2003-US27618	W 20030904
			US 2002-366354P	P 20020320
			US 2002-366440P	P 20020320
			US 2002-366449P	P 20020320
			US 2002-366470P	P 20020320
			US 2002-366479P	P 20020320
			US 2002-366487P	P 20020320
			AU 2003-230689	A3 20030319

AB The invention relates to a method for treating a disease characterized by a constrictive airway comprising administering to a patient in need thereof via inhalation a pharmaceutical composition comprising trospium, wherein said patient achieves an effective therapy for at least 10 h. The trospium composition is preferably a particulate formulation useful for administration via a dry powder inhaler. In a preferred embodiment, the composition further comprises a second active agent, such as a beta-2 agonist. A particularly preferred second active agent is formoterol, wherein the trospium, formoterol

composition is manufactured by spray drying a mixture comprising trospium and formoterol.

L9 ANSWER 2 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:250600 USPATFULL Full-text
 TITLE: Chromane Derivatives
 INVENTOR(S): Matsumoto, Yukari, Chita-gun, JAPAN
 Shimokawa, Hirohisa, Chita-gun, JAPAN
 Yamagishi, Tatsuya, Chita-gun, JAPAN
 PATENT ASSIGNEE(S): Pfizer Inc (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007219237	A1	20070920
APPLICATION INFO.:	US 2007-687781	A1	20070319 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-804872P	20060615 (60)
	US 2006-783663P	20060317 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1-10	
LINE COUNT:	2750	

AB This invention relates to compounds of the formula (I):

##STR1##

or a pharmaceutically acceptable salt thereof, wherein: R.¹, R.², R.³, R.⁴, R.⁵, R.⁶, R.⁷, R.⁸ A and B are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), laryngopharyngeal reflux disease, peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of Helicobacter pylori, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, cancer, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

L9 ANSWER 3 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:170907 USPATFULL Full-text
 TITLE: Compounds having lysophosphatidic acid receptor antagonism and uses thereof
 INVENTOR(S): Tanaka, Motoyuki, Mishima-gun, JAPAN
 Nakade, Shinji, Tsukuba-shi, JAPAN
 Takaoka, Yoshikazu, Mishima-gun, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007149595	A1	20070628

APPLICATION INFO.: US 2004-583469 A1 20041217 (10)
 WO 2004-JP19456 20041217
 20060619 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-422431	20031219
	JP 2004-101378	20040330
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5101	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a compound represented by formula (I):
 ##STR1## (wherein the symbols in formula were described in the description), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention binds to and is antagonistic to an LPA receptor (particularly, EDG-2), it is useful for prevention and/or treatment of urinary system disease (prostatic hypertrophy or neurogenic bladder dysfunction disease, spinal cord neoplasm, nucleous hernia, spinal canal stenosis, diseases caused by diabetes, occlusion disease of lower urinary tract, inflammatory disease of lower urinary tract, and polyuria), carcinoma-associated disease, proliferative disease, inflammation system disease, immune system disease, disease by secretory dysfunction, brain-related disease and/or chronic disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2007:162891 USPATFULL Full-text
 TITLE: Chromane Substituted Benzimidazole Derivatives
 INVENTOR(S): Hanazawa, Takeshi, Chita-gun, JAPAN
 Koike, Hiroki, Chita-gun, JAPAN
 PATENT ASSIGNEE(S): Pfizer Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007142448	A1	20070621
APPLICATION INFO.:	US 2006-612583	A1	20061219 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-752181P	20051219 (60)
	US 2006-802944P	20060523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3694	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, wherein: A, B, X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are each as described herein or a pharmaceutically acceptable salt, and compositions

containing such compounds and the use of such compounds in the treatment of a condition mediated by acid pump antagonistic activity such as, but not limited to, as gastrointestinal disease, gastroesophageal disease, gastroesophageal reflux disease (GERD), peptic ulcer, gastric ulcer, duodenal ulcer, NSAID-induced ulcers, gastritis, infection of *Helicobacter pylori*, dyspepsia, functional dyspepsia, Zollinger-Ellison syndrome, non-erosive reflux disease (NERD), visceral pain, heartburn, nausea, esophagitis, dysphagia, hypersalivation, airway disorders or asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:75023 USPATFULL Full-text
 TITLE: Mucoactive agents for treating a pulmonary disease
 INVENTOR(S): Morton, David, Wiltshire, UNITED KINGDOM
 Ganderton, David, Wiltshire, UNITED KINGDOM
 Staniforth, John, Wiltshire, UNITED KINGDOM
 Kamlag, Yorick, Wiltshire, UNITED KINGDOM
 PATENT ASSIGNEE(S): Vectura Ltd., Chippenham, Wiltshire, GBN, UNITED KINGDOM, SN14 6FH (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007065373	A1	20070322
APPLICATION INFO.:	US 2004-571184	A1	20040915 (10)
	WO 2004-GB3932		20040915
			20060717 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-21611	20030915
	GB 2003-27723	20031128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE, 14TH FLOOR, NEW YORK, NY, 10018, US	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1903	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to mucoactive agents, such as heparin which are useful in the treatment of diseases where excess mucus is present in the respiratory tract, such as cystic fibrosis and chronic obstructive pulmonary disease. In particular, the invention relates to pharmaceutical compositions for administration by pulmonary inhalation. It also relates to methods for producing particles suitable for pulmonary inhalation, such as spray drying or jet milling.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2007:12284 USPATFULL Full-text
 TITLE: Safety containers for biologically active substances and method for producing said container
 INVENTOR(S): Bensmann, Hubert, Halle/Westfalen, GERMANY, FEDERAL REPUBLIC OF
 Kranzmann, Heiko, Bielefeld, GERMANY, FEDERAL REPUBLIC

OF
 Milsmann, Eckhard, Bielefeld, GERMANY, FEDERAL REPUBLIC
 OF
 Wichert, Burkhard, Bielefeld, GERMANY, FEDERAL REPUBLIC
 OF

PATENT ASSIGNEE(S): Baxter International Inc, Deerfield, IL, UNITED STATES, 60015 (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2007010700	A1	20070111
APPLICATION INFO.:	US 2004-541692	A1	20040109 (10)
	WO 2004-EP98		20040109
			20060829 PCT 371 date

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2003-60438822	20030109
	DE 2001-103003231	20010109

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SENNIGER POWERS, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102, US

NUMBER OF CLAIMS: 26

EXEMPLARY CLAIM: 1-56

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 2108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to safety containers for biologically active substances, in particular cytostatic agents, said container having increased or higher fracture strength and shatterproof qualities, in addition to an uncontaminated exterior. The invention also relates to a method for producing said containers and to the use of a medium containing at least one polymer for decontaminating the exterior of a container that is filled with a biologically active substance, sealed and optionally labelled.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2006:301136 USPATFULL Full-text

TITLE: Dry powder composition comprising co-jet milled particles for pulmonary inhalation

INVENTOR(S): Morton, David, Wiltshire, UNITED KINGDOM

Staniforth, John, Wiltshire, UNITED KINGDOM

PATENT ASSIGNEE(S): Vectura Limited, Chippenham, UNITED KINGDOM (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2006257491	A1	20061116
APPLICATION INFO.:	US 2004-571146	A1	20040915 (10)
	WO 2004-GB3996		20040915
			20060717 PCT 371 date

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	GB 2003-21612	20030915
	GB 2003-21608	20030915
	GB 2003-21607	20030915

GB 2004-9133 20040423

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 SEVENTH AVENUE,
 14TH FLOOR, NEW YORK, NY, 10018, US
 NUMBER OF CLAIMS: 41
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Page(s)
 LINE COUNT: 1996

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to particles and to methods of making particles. In particular, the invention relates to methods of making composite active particles comprising a pharmaceutically active material for pulmonary inhalation, the method comprising a jet milling process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:17275 USPATFULL Full-text
 TITLE: Solid peptide preparations for inhalation and their preparation
 INVENTOR(S): Lizio, Rosario, Buttelbörn, GERMANY, FEDERAL REPUBLIC OF
 Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF
 Sarlikiotis, Werner, Peania, GREECE
 Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005014677	A1	20050120
APPLICATION INFO.:	US 2004-808239	A1	20040323 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-944060, filed on 31 Aug 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10043509	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GOODWIN PROCTER L.L.P, 103 EISENHOWER PARKWAY, ROSELAND, NJ, 07068	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	731	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2005:3763 USPATFULL Full-text
 TITLE: Diagnostic/therapeutic agents
 INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
 Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY
 Tolleshaug, Helge, Oslo, NORWAY
 Cuthbertson, Alan, Oslo, NORWAY
 Godal, Aslak, Oslo, NORWAY
 Hoff, Lars, Oslo, NORWAY
 Gogstad, Geir, Oslo, NORWAY
 Bryn, Klaus, Oslo, NORWAY
 Naevestad, Anne, Oslo, NORWAY
 Lovhaug, Dagfinn, Oslo, NORWAY
 Hellebust, Halldis, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S) : Amersham Health AS, Oslo, NORWAY (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:

US 2005002865 A1 20050106

APPLICATION INFO.:

US 2003-734730 A1 20031215 (10)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 2001-925715, filed on 10 Aug 2001, GRANTED, Pat. No. US 6680047 Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, GRANTED, Pat. No. US 6331289

NUMBER	DATE
--------	------

PRIORITY INFORMATION:

GB 1996-22366	19961028
GB 1996-22369	19961028
GB 1997-2195	19970204
GB 1997-8265	19970424
GB 1997-11837	19970606
GB 1997-11839	19970606
US 1997-49263P	19970607 (60)
US 1997-49264P	19970606 (60)
US 1997-49266P	19970607 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Li CAI, Amersham Health, Inc., 101 Carnegie Center, Princeton, NJ, 08540-6231

NUMBER OF CLAIMS:

38

EXEMPLARY CLAIM:

1

LINE COUNT:

5221

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2004:184041 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S): Klaveness, Jo, Oslo, NORWAY

Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY

Tolleshaug, Helge, Oslo, NORWAY

Naevestad, Anne, Oslo, NORWAY

Hellebust, Halldis, Oslo, NORWAY

Hoff, Lars, Oslo, NORWAY

Cuthbertson, Alan, Oslo, NORWAY

Lovhaug, Dagfinn, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY
 PATENT ASSIGNEE(S) : NYCOMED IMAGING AS (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004141922	A1	20040722
APPLICATION INFO.:	US 2003-722075	A1	20031126 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-765614, filed on 22 Jan 2001, ABANDONED Continuation of Ser. No. US 1997-960054, filed on 29 Oct 1997, GRANTED, Pat. No. US 6261537 Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997, GRANTED, Pat. No. US 6264917		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970606 (60)
	US 1997-49265P	19970606 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Li CAI, Amersham Health, Inc., 101 Carnegie Center, Princeton, NJ, 08540-6231

NUMBER OF CLAIMS: 37
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 2 Drawing Page(s)
 LINE COUNT: 6450

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilised by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2004:56968 USPATFULL Full-text
 TITLE: Inhalable sustained therapeutic formulations
 INVENTOR(S): Basu, Sujit K., Cambridge, MA, UNITED STATES
 Caponetti, Giovanni, Piacenza, ITALY
 Clarke, Robert, Canton, MA, UNITED STATES
 Elbert, Katharina J., Cambridge, MA, UNITED STATES
 PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004042970	A1	20040304
APPLICATION INFO.:	US 2003-392333	A1	20030319 (10)

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION: US 2002-366479P 20020320 (60)
 US 2002-366449P 20020320 (60)
 US 2002-366354P 20020320 (60)
 US 2002-366470P 20020320 (60)
 US 2002-366487P 20020320 (60)
 US 2002-366440P 20020320 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Elmore Craig, P.C., 209 Main Street, No. Chelmsford, MA, 01863
 NUMBER OF CLAIMS: 58
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 11 Drawing Page(s)
 LINE COUNT: 2838

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 15 USPATFULL on STN
 ACCESSION NUMBER: 2003:329808 USPATFULL Full-text
 TITLE: Inhalable formulations for sustained release
 INVENTOR(S): Basu, Sujit K., Cambridge, MA, UNITED STATES
 Elbert, Katharina, Cambridge, MA, UNITED STATES
 Hrkach, Jeffrey, Cambridge, MA, UNITED STATES
 Caponetti, Giovanni, Piacenza, ITALY
 PATENT ASSIGNEE(S): Advanced Inhalation Research, Inc., Cambridge, MA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232019	A1	20031218
APPLICATION INFO.:	US 2003-371398	A1	20030220 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-427845P	20021120 (60)
	US 2002-359466P	20020222 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Elmore Craig, P.C., 209 Main Street, No. Chelmsford, MA, 01863	
NUMBER OF CLAIMS:	123	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2281	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is based, in part, on the unexpected discovery that aerosol particle formulations for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising an asymmetric phospholipid exhibit sustained release and/or sustained action of the agent. In some embodiments, as an alternative to one or more asymmetric phospholipids or in addition to one or more asymmetric phospholipids, the instant particles comprise one or more glycerol fatty acid esters. The present invention is directed to spray dried non-polymeric particles for pulmonary delivery and sustained release of a therapeutic, prophylactic or diagnostic agent and methods for delivery of said particles to the pulmonary system, the particles comprising a therapeutic, prophylactic or diagnostic agent and an asymmetric phospholipid and/or one or more glycerol fatty acid esters. In one embodiment, the particles comprise a combination of phospholipids wherein at least one of the phospholipids is an asymmetric phospholipid. In another embodiment, the particles comprise one or more phospholipids and one or more glycerol fatty acid esters.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:227675 USPATFULL Full-text

TITLE: Solid peptide preparations for inhalation and their preparation

INVENTOR(S): Lizio, Rosario, Buttelborn, GERMANY, FEDERAL REPUBLIC OF
Damm, Michael, Rodermark, GERMANY, FEDERAL REPUBLIC OF
Sarlikiotis, Werner, Peania, GREECE
Wolf-Heuss, Elisabeth, Mosbach, GERMANY, FEDERAL
REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002122826	A1	20020905
APPLICATION INFO.:	US 2001-944060	A1	20010831 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2000-10043509	20000901
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Goodwin Procter L.L.P., 599 Lexington Avenue, 40th floor, New York, NY, 10022	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	764	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to solid pharmaceutical preparations, in particular for inhalatory administration in mammals, their preparation and their use such as, for example, in powder inhalers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:191154 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S): Klaveness, Jo, Oslo, NORWAY
Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY
 Tolleshaug, Helge, Oslo, NORWAY
 Cuthbertson, Alan, Oslo, NORWAY
 Godal, Aslak, Oslo, NORWAY
 Hoff, Lars, Oslo, NORWAY
 Gogstad, Geir, Oslo, NORWAY
 Bryn, Klaus, Oslo, NORWAY
 Naevestad, Anne, Oslo, NORWAY
 Lovhaug, Dagfinn, Oslo, NORWAY
 Hellebust, Halldis, Oslo, NORWAY
 Solbakken, Magne, Oslo, NORWAY
 Nycomed Imaging AS (non-U.S. corporation)

PATENT ASSIGNEE(S) :

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002102217	A1	20020801
	US 6680047	B2	20040120
APPLICATION INFO.:	US 2001-925715	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-959206, filed on 28 Oct 1997, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22369	19961028
	GB 1997-2195	19970204
	GB 1997-8265	19970424
	GB 1997-11837	19970606
	GB 1997-11839	19970606
	US 1997-49263P	19970607 (60)
	US 1997-49264P	19970606 (60)
	US 1997-49266P	19970607 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

Richard E. Fichter, BACON & THOMAS, PLLC, Fourth Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176

NUMBER OF CLAIMS:

38

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

1 Drawing Page(s)

LINE COUNT:

5190

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 15 USPATFULL on STN

ACCESSION NUMBER: 2002:191152 USPATFULL Full-text

TITLE: Diagnostic/therapeutic agents

INVENTOR(S) :

Klaveness, Jo, Oslo, NORWAY

Rongved, Pal, Oslo, NORWAY

Hogset, Anders, Oslo, NORWAY

Tolleshaug, Helge, Oslo, NORWAY

Naevestad, Anne, Oslo, NORWAY

Hellebust, Halldis, Oslo, NORWAY

Hoff, Lars, Oslo, NORWAY

Cuthbertson, Alan, Oslo, NORWAY

Lovhaug, Dagfinn, Oslo, NORWAY

Solbakken, Magne, Oslo, NORWAY

PATENT ASSIGNEE(S): NYCOMED IMAGING AS (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2002102215 A1 20020801

APPLICATION INFO.: US 2001-765614 A1 20010122 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-960054, filed on 29 Oct 1997, PATENTED Continuation-in-part of Ser. No. US 1997-958993, filed on 28 Oct 1997, PATENTED

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	GB 1996-22366	19961028
	GB 1996-22367	19961028
	GB 1996-22368	19961028
	GB 1997-699	19970115
	GB 1997-8265	19970424
	GB 1997-11842	19970606
	GB 1997-11846	19970606
	US 1997-49264P	19970606 (60)
	US 1997-49265P	19970606 (60)
	US 1997-49268P	19970607 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BACON & THOMAS, PLLC, 4th Floor, 625 Slaters Lane, Alexandria, VA, 22314-1176

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 6583

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, having reporters comprising gas-filled microbubbles stabilized by monolayers of film-forming surfactants, the reporter being coupled or linked to at least one vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
----------------------	------------------	---------------

FULL ESTIMATED COST 89.58 132.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
--	------------------	---------------

CA SUBSCRIBER PRICE -1.56 -1.56

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:50:37 ON 02 OCT 2007